Company: Portola Pharmaceuticals
Based: South San Francisco, CA
Investors: Abingworth Management. Advanced Technology Ventures, AllianceBernstein, Alta Partners, Brookside International Incorporated, CIDC Consultants, Frazier Healthcare and Technology Ventures, Goldman, Sachs & Co., MPM Capital, Ontario Teachers Pension Plan, Prospect Venture Partners, Sutter Hill Ventures, T. Rowe Price Threshold, Partnerships, Undisclosed Investor
Scoop: Portola's lead drug is PRT054021, a therapy for prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation, and for secondary prevention of myocardial infarction and stroke. In July Portola turned in positive PRT054021 Phase II data for patients undergoing knee replacement surgery. In addition to PRT054021, Portola has a Phase I drug--PRT060128--for acute coronary syndrome, the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention and secondary prevention of MI and stroke. A Phase II trial of the drug is underway.